1
|
Pietrasik A, Gąsecka A, Pawłowski T, Sacha J, Grygier M, Bielawski G, Balak W, Sukiennik A, Burzyńska P, Witkowski A, Warniełło M, Rzeszutko Ł, Bartuś S, Pawlik A, Kaczyński M, Gil R, Kuliczkowski W, Reczuch K, Protasiewicz M, Kleczyński P, Wańczura P, Gurba S, Kochanowska A, Łomiak M, Cacko A, Skorupski W, Zarębiński M, Pawluczuk P, Włodarczak S, Włodarczak A, Ściborski K, Telichowski A, Pluciński M, Hiczkiewicz J, Konsek K, Hawranek M, Gąsior M, Peruga J, Fiutowski M, Romanek R, Kasprzyk P, Ciećwierz D, Ochała A, Wojakowski W, Legutko J, Kochman J. Multicenter registry of Impella-assisted high-risk percutaneous coronary interventions and cardiogenic shock in Poland (IMPELLA-PL). Kardiol Pol 2023; 81:1103-1112. [PMID: 37937354 DOI: 10.33963/v.kp.97218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 09/01/2023] [Indexed: 11/09/2023]
Abstract
BACKGROUND Impella is a percutaneous mechanical circulatory support device for treatment of cardiogenic shock (CS) and high-risk percutaneous coronary interventions (HR-PCIs). IMPELLA-PL is a national retrospective registry of Impella-treated CS and HR-PCI patients in 20 Polish interventional cardiological centers, conducted from January 2014 until December 2021. AIMS We aimed to determine the efficacy and safety of Impella using real-world data from IMPELLA-PL and compare these with other registries. METHODS IMPELLA-PL data were analyzed to determine primary endpoints: in-hospital mortality and rates of mortality and major adverse cardiovascular and cerebrovascular events (MACCE) at 12 months post-discharge. RESULTS Of 308 patients, 18% had CS and 82% underwent HR-PCI. In-hospital mortality rates were 76.4% and 8.3% in the CS and HR-PCI groups, respectively. The 12-month mortality rates were 80.0% and 18.2%, and post-discharge MACCE rates were 9.1% and 22.5%, respectively. Any access site bleeding occurred in 30.9% of CS patients and 14.6% of HR-PCI patients, limb ischemia in 12.7% and 2.4%, and hemolysis in 10.9% and 1.6%, respectively. CONCLUSIONS Impella is safe and effective during HR-PCIs, in accordance with previous registry analyses. The risk profile and mortality in CS patients were higher than in other registries, and the potential benefits of Impella in CS require investigation.
Collapse
Affiliation(s)
| | - Aleksandra Gąsecka
- Department of Cardiology, Medical University of Warsaw, Warszawa, Poland.
| | - Tomasz Pawłowski
- National Medical Institute of the Ministry of the Interior and Administration, Warszawa, Poland
| | - Jerzy Sacha
- Department of Cardiology, University Hospital in Opole, Opole, Poland
- Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
| | - Marek Grygier
- 1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland
| | - Gabriel Bielawski
- 2nd Department of Cardiology, Jan Biziel University Hospital No. 2, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Toruń, Poland
| | - Wojciech Balak
- 2nd Department of Cardiology, Jan Biziel University Hospital No. 2, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Toruń, Poland
| | - Adam Sukiennik
- Department of Cardiology and Internal Diseases, University Hospital No. 1, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Toruń, Poland
| | - Paulina Burzyńska
- Department of Cardiology and Internal Diseases, University Hospital No. 1, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Toruń, Poland
| | - Adam Witkowski
- Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warszawa, Poland
| | - Mateusz Warniełło
- Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warszawa, Poland
| | | | | | - Artur Pawlik
- Department of Cardiology, University Hospital, Kraków, Poland
| | - Mateusz Kaczyński
- National Medical Institute of the Ministry of the Interior and Administration, Warszawa, Poland
| | - Robert Gil
- National Medical Institute of the Ministry of the Interior and Administration, Warszawa, Poland
| | | | - Krzysztof Reczuch
- Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland
| | | | - Pawel Kleczyński
- Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland
| | - Piotr Wańczura
- College of Medical Sciences, University of Rzeszow, Rzeszów, Poland
| | - Sebastian Gurba
- College of Medical Sciences, University of Rzeszow, Rzeszów, Poland
| | - Anna Kochanowska
- Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
| | - Michał Łomiak
- Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
| | - Andrzej Cacko
- Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
| | | | - Maciej Zarębiński
- Independent Public Specialist Western Hospital John Paul II, Grodzisk Mazowiecki, Poland
| | - Piotr Pawluczuk
- Independent Public Specialist Western Hospital John Paul II, Grodzisk Mazowiecki, Poland
| | | | | | | | - Artur Telichowski
- Center for Heart Diseases, Military Hospital in Wroclaw, Wrocław, Poland
| | - Mieszko Pluciński
- Department of Interventional Cardiology and Cardiac Surgery, Collegium Medicum, University of Zielona Gora, Zielona Góra, Poland
- Department of Cardiology, Nowa Sól Multidisciplinary Hospital, Nowa Sól, Poland
| | - Jarosław Hiczkiewicz
- Department of Interventional Cardiology and Cardiac Surgery, Collegium Medicum, University of Zielona Gora, Zielona Góra, Poland
- Department of Cardiology, Nowa Sól Multidisciplinary Hospital, Nowa Sól, Poland
| | - Karolina Konsek
- 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
| | - Michał Hawranek
- 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
| | - Mariusz Gąsior
- 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
| | - Jan Peruga
- 1st Department of Cardiology, Bieganski Hospital, Medical University, Łódź, Poland
| | - Marcin Fiutowski
- 1st Department of Cardiology, Bieganski Hospital, Medical University, Łódź, Poland
| | - Robert Romanek
- Department of Cardiology and Cardiac Surgery, 10th Military Hospital and Polyclinic, Bydgoszcz, Poland
| | - Piotr Kasprzyk
- 1st Department of Cardiology, Medical University of Gdansk, Gdańsk, Poland
| | - Dariusz Ciećwierz
- 1st Department of Cardiology, Medical University of Gdansk, Gdańsk, Poland
| | - Andrzej Ochała
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Wojciech Wojakowski
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Jacek Legutko
- Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland
| | - Janusz Kochman
- Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
| |
Collapse
|
2
|
Balak W, Wiśniewska J, Ziółkowski M, Walukiewicz M, Bielawski G, Grześk G. High‑risk coronary angioplasty protected by an Impella pump combined with simultaneous iliac artery angioplasty. Kardiol Pol 2019; 77:726-727. [PMID: 31237573 DOI: 10.33963/kp.14875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Wojciech Balak
- 2nd Department of Cardiology,Ludwik Rydygier CollegiumMedicumin Bydgoszcz,Nicolaus CopernicusUniversityin Toruń, Jan BizielUniversityHospitalNo. 2 in Bydgoszcz, Bydgoszcz, Poland
| | - Joanna Wiśniewska
- Department of Vascular and Internal Diseases, Jan Biziel University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Poland
| | - Michał Ziółkowski
- 2nd Department of Cardiology,Ludwik Rydygier CollegiumMedicumin Bydgoszcz,Nicolaus CopernicusUniversityin Toruń, Jan BizielUniversityHospitalNo. 2 in Bydgoszcz, Bydgoszcz, Poland
| | - Marcin Walukiewicz
- 2nd Department of Cardiology,Ludwik Rydygier CollegiumMedicumin Bydgoszcz,Nicolaus CopernicusUniversityin Toruń, Jan BizielUniversityHospitalNo. 2 in Bydgoszcz, Bydgoszcz, Poland
| | - Gabriel Bielawski
- 2nd Department of Cardiology,Ludwik Rydygier CollegiumMedicumin Bydgoszcz,Nicolaus CopernicusUniversityin Toruń, Jan BizielUniversityHospitalNo. 2 in Bydgoszcz, Bydgoszcz, Poland
| | - Grzegorz Grześk
- 2nd Department of Cardiology,Ludwik Rydygier CollegiumMedicumin Bydgoszcz,Nicolaus CopernicusUniversityin Toruń, Jan BizielUniversityHospitalNo. 2 in Bydgoszcz, Bydgoszcz, Poland
| |
Collapse
|
13
|
Sinkiewicz W, Błazejewski J, Bujak R, Zekanowska E, Sobański P, Kubica J, Dudziak J, Karasek D, Małyszka P, Balak W, Demidowicz K. Immunoglobulin E as a marker of the atherothrombotic process in patients with acute myocardial infarction. Cardiol J 2007; 14:266-273. [PMID: 18651471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
BACKGROUND Clot formation is a crucial moment in the patophysiology of acute coronary syndromes. The aim of this research was to assess the relationship between immunoglobulin E (IgE), lipid parameters and chosen hemostatic markers. The role of IgE as a possible participant in the atherothrombotic process was also investigated. METHODS A total of 80 patients with acute myocardial infarction (MI) was enrolled in the study. Concentrations of IgE, plasma lipid parameters, lipoprotein(a), markers of thrombin generation (TAT, AT III), markers of fibrinolysis (tPA:Ag, PAI-1:Ag, PAP, D-dimers) and markers of endothelial damage (von Willebrand factor) were measured in blood samples collected immediately after admission, before any treatment administration. RESULTS In patients with acute MI and with IgE concentration above 100 kU/l, IgE values were strongly, positively correlated with LDL concentration (p < 0.05), lipoprotein(a) concentration (p < 0.02) and negatively correlated with HDL plasma levels (p < 0.02). Exclusion of patients with IgE concentration lower than 150 kU/l strengthened the correlation between IgE concentration and LDL (p < 0.002) and lipoprotein(a) (p < 0.01) levels. It also revealed a significant correlation between IgE and TAT (p < 0.001), IgE and AT III (p < 0.002), and IgE and D-dimers (p < 0.05). IgE and TAT values measured 7, 14 and 40 days after infarction also showed significant positive correlation between increments of these parameters. CONCLUSIONS In patients with acute MI, a significant increase of thrombinogenesis and fibrinolysis markers is observed. Positive correlation between IgE concentration above 100 kU/l and markers of thrombinogenesis activation, lipid parameters and lipoprotein(a) levels, with significance increasing with IgE concentration and constant positive correlation between increments of IgE and TAT, can serve as evidence of IgE participation in the atherothrombotic process. (Cardiol J 2007; 14: 266-273).
Collapse
|